- Home
- ARHS vs LXRX Comparison
ARHS vs LXRX Comparison
Compare ARHS & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARHS | LXRX |
|---|---|---|
| Founded | 1986 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 956.8M | 996.7M |
| IPO Year | 2021 | 2000 |
Fundamental Metrics
Financial Performance| Metric | ARHS | LXRX |
|---|---|---|
| Price | $11.11 | $1.60 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 6 |
| Target Price | ★ $10.85 | $4.55 |
| AVG Volume (30 Days) | 1.5M | ★ 2.6M |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | ★ 3.26% | N/A |
| EPS Growth | N/A | ★ 77.78 |
| EPS | ★ 0.30 | N/A |
| Revenue | ★ $1,379,222,000.00 | $49,803,000.00 |
| Revenue This Year | $5.94 | N/A |
| Revenue Next Year | $6.53 | N/A |
| P/E Ratio | $35.67 | ★ N/A |
| Revenue Growth | 8.51 | ★ 60.24 |
| 52 Week Low | $5.57 | $1.10 |
| 52 Week High | $12.08 | $2.68 |
Technical Indicators
Market Signals| Indicator | ARHS | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 69.51 | 33.71 |
| Support Level | $9.42 | $1.50 |
| Resistance Level | $11.23 | $1.81 |
| Average True Range (ATR) | 0.42 | 0.07 |
| MACD | 0.10 | -0.00 |
| Stochastic Oscillator | 97.66 | 24.20 |
Price Performance
Historical ComparisonAbout ARHS Arhaus Inc.
Arhaus Inc is a growing lifestyle brand and omnichannel retailer of premium home furniture. The company offers merchandise in several categories, including furniture, outdoor, lighting, textiles, and decor through its Retail and e-commerce sales channels.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.